News Releases

Date	Title and Summary	View
Dec 02, 2020	Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration
Nov 25, 2020	European Commission Approves Janssen’s TREMFYA®▼ (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)
Nov 13, 2020	Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa
Nov 12, 2020	Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)/DARZALEX® (daratumumab) Subcutaneous (SC) Formulation in Combination With Pomalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma
Nov 09, 2020	New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
Nov 06, 2020	Johnson & Johnson to Host Virtual Medical Devices Update Event will focus on strategy and capabilities in digital surgery and highlight key innovations and initiatives expected to drive competitive growth and continued momentum across Johnson & Johnson Medical Devices Companies NEW BRUNSWICK, N.J. , Nov. 6, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:
Nov 05, 2020	Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
Nov 02, 2020	Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults
Oct 26, 2020	Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease
Oct 22, 2020	Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2020 NEW BRUNSWICK, N.J. , Oct. 22, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2020 of $1.01 per share on the company's common stock. The dividend is payable on December 8, 2020 to shareholders of